Academic Journal
The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers
| العنوان: | The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers |
|---|---|
| المؤلفون: | Chung, Heekyoung, Jung, Ji-Youn, Cho, Sung Dae, Hong, Kyung-A., Kim, Hyun-Jun, Shin, Dong-Hui, Kim, Hwan, Kim, Hea Ok, Shin, Dae Hong, Lee, Hyuk Woo, Jeong, Lak Shin, Kong, Gu |
| المساهمون: | Cho, Sung Dae, Jeong, Lak Shin |
| بيانات النشر: | American Association for Cancer Research |
| سنة النشر: | 2018 |
| المجموعة: | Seoul National University: S-Space |
| مصطلحات موضوعية: | IB-MECA, MONOCLONAL-ANTIBODY, CELL-GROWTH, APOPTOSIS, INHIBITION, EXPRESSION, PHOSPHORYLATION, ACTIVATION, THERAPY, TARGET |
| الوصف: | Agonists to A3 adenosine receptor (A3AR) have been reported to inhibit cell growth and/or induce apoptosis in various tumors. We tested the effect of a novel A3AR agonist generically known as LJ-529 in breast cancer cells. Anchorage-dependent cell growth and in vivo tumor growth were attenuated by LJ-529, independently of its estrogen receptor (ER) alpha status. In addition, apoptosis was induced as evidenced by the activation of caspase-3 and c-poly (ADP)ribose polymerase. Furthermore, the Wnt signaling pathway was down-regulated and P27(kip) was induced by LJ-529. In ER-positive cells, the expression of ER was down-regulated by LJ-529, which might have additionally contributed to attenuated cell proliferation. In ER-negative, c-ErbB2-overexpressing SK-BR-3 cells, the expression of c-ErbB2 and its downstream extracellular signal-regulated kinase pathway were down-regulated by LJ-529. However, such effect of LJ-529 acted independently of its receptor because no A3AR was detected by reverse transcription-PCR in all four cell lines tested. In conclusion, our novel findings open the possibility of LJ-529 as an effective therapeutic agent against both ER-positive and ER-negative breast cancers, particularly against the more aggressive ER-negative, c-ErbB2-overexpressing types. ; N ; 1 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1535-7163 |
| Relation: | Molecular Cancer Therapeutics, Vol.5 No.3, pp.685-692; https://hdl.handle.net/10371/208988; 000236444500024; 2-s2.0-33645472346; 27777 |
| DOI: | 10.1158/1535-7163.MCT-05-0245 |
| الاتاحة: | https://hdl.handle.net/10371/208988 https://doi.org/10.1158/1535-7163.MCT-05-0245 |
| رقم الانضمام: | edsbas.C37AEB01 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15357163 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-05-0245 |